Related Experiment Video
Updated: Aug 15, 2026
Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
Y Zlotnik1, M Patya, A Vanichkin
1Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Rabin Medical Center, Beilinson Campus, Petah-Tikva 49100, Israel.
Abstract:
Intestinal injury that results from chemotherapy belongs to the major factors of dose-limitation in tumour therapy. The tyrphostins AG1714 and AG1801 reduce cisplatin and 5-FU-induced small intestinal mucosal damage, using a quantitative biochemical assay. The assay is based on the determination of the enzymatic activity of gamma-glutamyl transpeptidase, a marker of the brush border epithelium of the small intestine.
Insights
Tyrphostins AG1714 and AG1801 protect against chemotherapy-induced intestinal damage. These compounds reduce small intestinal mucosal injury caused by cisplatin and 5-fluorouracil (5-FU).
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Chemotherapy-induced intestinal injury is a significant limitation in cancer treatment.
- This damage affects patient quality of life and treatment efficacy.
Purpose of the Study:
- To evaluate the protective effects of tyrphostins AG1714 and AG1801 against chemotherapy-induced small intestinal mucosal damage.
- To assess the efficacy of these compounds in reducing damage from cisplatin and 5-fluorouracil (5-FU).
Main Methods:
- Utilized a quantitative biochemical assay to measure intestinal mucosal damage.
- Assayed the enzymatic activity of gamma-glutamyl transpeptidase, a marker for small intestine brush border epithelium.
Main Results:
- Tyrphostins AG1714 and AG1801 demonstrated a reduction in chemotherapy-induced small intestinal mucosal damage.
- The compounds effectively mitigated damage caused by both cisplatin and 5-FU.
Conclusions:
- Tyrphostins AG1714 and AG1801 show potential as therapeutic agents to prevent or reduce chemotherapy-related gastrointestinal side effects.
- Further research may explore their clinical application in cancer therapy to improve patient outcomes.
More Related Videos
06:04Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019